Bristol-Myers Squibb reported higher than expected quarterly earnings on Tuesday, helped by cost cuts and lower taxes. There were concerns over a possible delay in completing its marketing application for a high-profile cancer drug. BMY posted Q1 earnings of 56 cents per share, beating estimates of 43 cents a share, while revenue dipped to $3.81 billion, missing estimates of $3.89 billion. Bristol-Myers Squibb also announced the acquisition of iPierian for $175 million.

If you liked this article you might like

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

Bristol-Myers 'Is Back' and Could Soar Another 14%

Bristol-Myers 'Is Back' and Could Soar Another 14%

These Were the 3 Hottest Stories on Wall Street Thursday

These Were the 3 Hottest Stories on Wall Street Thursday

Rock and Roll: Bristol-Myers Squibb Is Breaking Out

Rock and Roll: Bristol-Myers Squibb Is Breaking Out

Dow Soars Over 250 Points to Post Its Fourth Straight Day of Gains